News - Sprycel


Current filters:


Popular Filters

CML drug revenue in Japan to grow, despite global decline, says GlobalData


Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib


The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

"NICE" news for Novartis CML drugs, but not for Bristol-Myers


In final draft guidance issued this morning, UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Mixed NICE recommendations for CML and diabetes drugs


In a batch of final guidances released this morning by the UK’s drug watchdog the Institute for…

Bristol-Myers SquibbBydureonDiabetesEli LillyEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

FDA warns of pulmonary arterial hypertension risk with Bristol-Myers’ Sprycel


The US Food and Drug Administration is warning the public that drug major Bristol-Myers Squibb’s…

Bristol-Myers SquibbNorth AmericaOncologyPharmaceuticalRegulationSprycel

UK’s NICE says “no” to Novartis Tasigna and B-MS Sprycel, but better news on Afinitor


The UK’s drug rationing body the National Institute for Health and Clinical Excellence (NICE) yesterday…

AfinitorBristol-Myers SquibbGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Back to top